List All Myelodysplastic/ Myeloproliferative Syndromes Trials

Myelodysplastic/Myeloproliferative Syndromes


INC424 for Polycythemia Vera (2490)
Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care

Investigator: Bart Lee Scott, MD;   Conditions: Polycythemia Vera;    Status: Recruiting;   Study ID: NCT01243944

Lenalidomide With or Without Epoetin Alfa for Myelodysplastic Syndrome
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia

Investigator: Fred Appelbaum, MD;   Conditions: Myelodysplastic Syndromes;    Status: Recruiting;   Study ID: NCT00843882

Radioimmunotherapy + SCT for Advanced AML, ALL, or MDS
Hematopoietic Cell Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate

Investigator: John M. Pagel, MD;   Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome;    Status: Recruiting;   Study ID: NCT00988715

Decitabine Followed by Idarubicin and Cytarabine for AML or MDS
Phase II Trial Examining Epigenetic Priming With Decitabine Followed by Idarubicin and Cytarabine for Patients With Relapsed or Refractory AML

Investigator: Derek L. Stirewalt, MD;   Conditions: Leukemia, Myelodysplastic Syndromes;    Status: Recruiting;   Study ID: NCT01607645

Treosulfan and Fludarabine + Low-Dose TBI as Transplant Conditioning for MDS or AML Patients (2524)
A Randomized Phase II Multi-center Study of Treosulfan, Fludarabine and Low-Dose TBI as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)

Investigator: Joachim Deeg, MD;   Conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01894477

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride for Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) (2734)
A Phase 1/2 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Investigator: Roland Walter, MD;   Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic and Myeloproliferative Syndromes (MDS and MPD);    Status: Recruiting;   Study ID: NCT02044796

Decitabine and Cytarabine for Newly Diagnosed AML, High Risk MDS or MPN (9019)
Decitabine plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Investigator: Pamela Becker, MD, PhD;   Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MDS);    Status: Recruiting;   Study ID: NCT02121418

JAK-2 Inhibitor Prior to Transplant for Myelofibrosis (9033)
JAK-2 Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients with Primary and Secondary Myelofibrosis: A Prospective Study

Investigator: Rachel Salit;   Conditions: Myelofibrosis;    Status: Recruiting;   Study ID: NCT02251821

Allogeneic Transplants vs Hypomethylating/Best Supportive Care for MDS (9129)
A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome

Investigator: Bart Scott, MD;   Conditions: Myelodysplastic Syndrome;    Status: Recruiting;   Study ID: NCT02016781

Imetelstat for Myelofibrosis (9435)
A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects with Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor

Investigator: Bart Scott, MD;   Conditions: Myelofibrosis; Myeloproliferative Disorders (MPD);    Status: Recruiting;   Study ID: NCT02426086